Related Experiment Video

Updated: Aug 5, 2025

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
09:57

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles

Published on: December 23, 2016

8.9K

Glutathione-responsive and -exhausting metal nanomedicines for robust synergistic cancer therapy

Peng Liu1,2, Lu Hao1, Min Liu3,4

  • 1Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.

Frontiers in Bioengineering and Biotechnology
|March 27, 2023
PubMed

Insights

Metal nanomedicines targeting cancer cells by depleting glutathione (GSH) offer new therapeutic strategies. These GSH-responsive nanomaterials enhance cancer treatments like chemotherapy and photodynamic therapy.

Area of Science:

  • Nanomedicine
  • Oncology
  • Biochemistry

Background:

  • Cancer cells exhibit high glutathione (GSH) levels, which protect them from therapies like reactive oxygen species (ROS)-based treatments and chemotherapy.
  • Depleting intracellular GSH is a key strategy to overcome therapeutic resistance in cancer.

Purpose of the Study:

  • To review GSH-responsive and GSH-exhausting metal nanomedicines for targeted cancer therapy.
  • To discuss the application of these nanomedicines in various synergistic cancer treatment modalities.

Main Methods:

  • Review of literature on metal nanomedicines designed for GSH responsiveness and exhaustion.
  • Categorization of nanomedicines into inorganic nanomaterials, metal-organic frameworks (MOFs), and platinum-based nanomaterials.
  • Analysis of applications in chemotherapy, photodynamic therapy (PDT), sonodynamic therapy (SDT), chemodynamic therapy (CDT), ferroptotic therapy, and radiotherapy.

Main Results:

  • Several types of GSH-responsive and -exhausting metal nanomedicines have been developed for targeted tumor ablation.
  • These nanomedicines show promise in enhancing efficacy across multiple synergistic cancer therapy approaches.

Conclusions:

  • GSH-targeting metal nanomedicines represent a promising strategy for overcoming cancer cell resistance.
  • Further research into the future development and challenges of these nanomedicines is warranted for advanced cancer treatment.
Keywords:
TME regulationcancer therapyglutathione exhaustionmetal nanomaterialsreduction-response

More Related Videos

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.7K
Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy09:01

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Published on: May 22, 2020

3.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
284
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
14.7K